We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
THC Therapeutics Inc (CE) | USOTC:THCT | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0033 | 30 | 01:00:00 |
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2019
THC Therapeutics, Inc. |
(Exact name of registrant as specified in its charter) |
Nevada |
|
000-55994 |
|
26-0164981 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
645 Front St., #2202 San Diego, California |
|
92101 |
(Address of principal executive offices) |
|
(Zip Code) |
(702) 602-8422
(Registrant’s telephone number, including area code)
Not applicable
(former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
|
ITEM 1.02. TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.
On June 26, 2019, THC Therapeutics, Inc. (the “ Company ”) rescinded its acquisition agreements with ImpactPPA Limited, a Bahamian company (“ ImpactPPA ”), and Robot Cache, S.L., a Spanish limited company (“ Robot Cache ”), ImpactPPA agreed to return 6,000 shares of the Company’s Series A Preferred Stock to the Company for cancellation, and Robot Cache agreed to return 600,000 shares of the Company’s common stock to the Company for cancellation. As a result of the rescissions, the Company has no rights to equity or tokens of ImpactPPA or Robot Cache.
2 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THC Therapeutics, Inc. |
|||
Dated: July 2, 2019 | By: | /s/ Brandon Romanek | |
|
|
Brandon Romanek |
|
Chief Executive Officer |
3 |
1 Year THC Therapeutics (CE) Chart |
1 Month THC Therapeutics (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions